Organ-specific cancer metabolism and its potential for therapy

Handbook of Experimental Pharmacology

Volumn 233, Issue , 2016, Pages 321-353

  Elia, Ilaria ^a,b   Schmieder, Roberta ^a,b   Christen, Stefan ^a,b   Fendt, Sarah Maria ^a,b  

^a DEPARTMENT OF PLANT SYSTEMS BIOLOGY   (Belgium)

^b UNIVERSITY OF LEUVEN   (Belgium)

Author keywords

Cancer metabolism; Epigenetic drivers; Estrogen receptor positive breast cancer; Fatty acid metabolism; Genetic drivers; Gluconeogenesis; Glucose metabolism; Glutamine metabolism; Liver cancer; Metabolic depletion; Metabolic normalization; Metabolic therapy; Microenvironment; Mixed Warburg effect; Prostate cancer; Reverse Warburg effect; Serine metabolism; Tissue specific metabolism; Triple negative breast cancer; Warburg effect

Indexed keywords

3 HYDROXY 3 METHYLGLUTARYL COENZYME A; ACETYL COENZYME A ACYLTRANSFERASE; ACETYL COENZYME A CARBOXYLASE; ACYL COENZYME A DESATURASE; CHOLESTEROL; GLUCOSE 6 PHOSPHATE DEHYDROGENASE; GLUCOSE TRANSPORTER 1; GLUTAMINE; HEXOKINASE; HISTONE DEACETYLASE 2; HYPOXIA INDUCIBLE FACTOR 1ALPHA; INTERLEUKIN 6; KI 67 ANTIGEN; LACTATE DEHYDROGENASE; LIVER X RECEPTOR ALPHA; LIVER X RECEPTOR BETA; MALIC ACID; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 1; MEVALONATE KINASE; PHOSPHOGLYCERATE DEHYDROGENASE; PROTEIN KINASE B; PROTEIN P53; RAS PROTEIN; RITONAVIR; SHIKONIN; STEROL REGULATORY ELEMENT BINDING PROTEIN 1; STEROL REGULATORY ELEMENT BINDING PROTEIN 2; TAMOXIFEN; UNINDEXED DRUG; ZINC TRANSPORTER;

BREAST CANCER; CANCER CLASSIFICATION; CANCER COMBINATION CHEMOTHERAPY; CANCER GENETICS; CANCER HORMONE THERAPY; CANCER INCIDENCE; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER RISK; CANCER STAGING; CATABOLISM; CELL INTERACTION; EPIGENETICS; ESTROGEN RECEPTOR POSITIVE BREAST CANCER; GENE AMPLIFICATION; GENE EXPRESSION; GENE FUNCTION; GENE MUTATION; GLUCOSE METABOLISM; HUMAN; LIVER CANCER; LIVER CELL CARCINOMA; LIVER SURGERY; LIVER TRANSPLANTATION; MALIGNANT NEOPLASTIC DISEASE; MULTIPLE MYELOMA; NONHUMAN; ONCOGENE MYC; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; PROTEIN FUNCTION; PROTEIN MODIFICATION; RADIOFREQUENCY ABLATION; SIGNAL TRANSDUCTION; TRIPLE NEGATIVE BREAST CANCER; TUMOR DIFFERENTIATION; TUMOR MICROENVIRONMENT; ANTIBODY SPECIFICITY; BREAST TUMOR; FEMALE; LIVER TUMOR; MALE; METABOLISM; NEOPLASMS; PROSTATE TUMOR;

BREAST NEOPLASMS; FEMALE; HUMANS; LIVER NEOPLASMS; MALE; NEOPLASMS; ORGAN SPECIFICITY; PROSTATIC NEOPLASMS; TUMOR MICROENVIRONMENT;

EID: 84961589787     PISSN: 01712004     EISSN: 18650325     Source Type: Book Series    
DOI: 10.1007/164_2015_10     Document Type: Chapter

References (228)

1. Adamis S, Varkarakis IM (2014) Defining prostate cancer risk after radical prostatectomy. Eur J Surg Oncol 40(5):496-504.
2. Adeva M et al (2013) Enzymes involved in l-lactate metabolism in humans. Mitochondrion 13 (6):615-629.
3. Albers MJ et al (2008) Hyperpolarized 13C lactate, pyruvate, and alanine: noninvasive biomarkers for prostate cancer detection and grading. Cancer Res 68:8607-8615.
4. Aleksandrova K et al (2014) Inflammatory and metabolic biomarkers and risk of liver and biliary tract cancer. Hepatology 60:858-871.
5. Alvarez JV et al (2014) Oncogene pathway activation in mammary tumors dictates [18F]-FDGPET uptake. Cancer Res 74:7583-759.
6. Chen J et al (2011) Shikonin and its analogs inhibit cancer cell glycolysis by targeting tumor pyruvate kinase-M2. Oncogene 30(42):4297-4306.
7. Chen P et al (2014) Higher dietary folate intake reduces the breast cancer risk: a systematic review and meta-analysis. Br J Cancer 110(9):2327-2338.
8. Chesney J et al (2014) Fructose-2,6-bisphosphate synthesis by 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase 4 (PFKFB4) is required for the glycolytic response to hypoxia and tumor growth. Oncotarget 5(16):6670-6686.
9. Choi J et al (2013) Metabolic interaction between cancer cells and stromal cells according to breast cancer molecular subtype. Breast Cancer Res 15(5):R78.
10. Clem B et al (2008) Small-molecule inhibition of 6-phosphofructo-2-kinase activity suppresses glycolytic flux and tumor growth. Mol Cancer Ther 7(1):110-120.
11. Costello LC et al (2004) Role of zinc in the pathogenesis and treatment of prostate cancer: critical issues to resolve. Prostate Cancer Prostatic Dis 7:111-117.
12. Costello LC, Franklin RB, Feng P (2005) Mitochondrial function, zinc, and intermediary metabolism relationships in normal prostate and prostate cancer. Mitochondrion 5:143-153.
13. Dang CV (2012a) Links between metabolism and cancer. Genes Dev 26(9):877-890.
14. Dang CV (2012b) MYC on the path to cancer. Cell 149(1):22-35.
15. Dang L et al (2009) Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. Nature 462 (7274):739-744.
16. Dang L, Jin S, Su SM (2010) IDH mutations in glioma and acute myeloid leukemia. Trends Mol Med 16(9):387-397.
17. De Bock K et al (2013) Role of PFKFB3-driven glycolysis in vessel sprouting. Cell 154 (3):651-663.
18. De Schrijver E et al (2003) RNA interference-mediated silencing of the fatty acid synthase gene attenuates growth and induces morphological changes and apoptosis of LNCaP prostate cancer cells. Cancer Res 63:3799-3804.
19. DeBerardinis RJ, Thompson CB (2012) Cellular metabolism and disease: what do metabolic outliers teach us? Cell 148(6):1132-1144.
20. Dennison JB et al (2013) Lactate dehydrogenase B: a metabolic marker of response to neoadjuvant chemotherapy in breast cancer. Clin Cancer Res 19(13):3703-3713.
21. Di Tommaso L et al (2009) The application of markers (HSP70 GPC3 and GS) in liver biopsies is useful for detection of hepatocellular carcinoma. J Hepatol 50(4):746-754.
22. DiPaola RS et al (2008) Therapeutic starvation and autophagy in prostate cancer: a new paradigm for targeting metabolism in cancer therapy. Prostate 68:1743-1752.
23. Dimitrov L, Hong CS, Yang C, Zhuang Z, Heiss JD (2015) New developments in the pathogenesis and therapeutic targeting of the IDH1 mutation in glioma. Int J Med Sci 12(3):201-213.
24. Dohnal V, Wu Q, Kuca K (2014) Metabolism of aflatoxins: key enzymes and interindividual as well as interspecies differences. Arch Toxicol 88(9):1635-1644.
25. Doyen J et al (2014) Expression of the hypoxia-inducible monocarboxylate transporter MCT4 is increased in triple negative breast cancer and correlates independently with clinical outcome. Biochem Biophys Res Commun 451(1):54-61.
26. Draoui N, Feron O (2011) Lactate shuttles at a glance: from physiological paradigms to anticancer treatments. Dis Model Mech 4:727-732.
27. Dunbar EM et al (2014) Phase 1 trial of dichloroacetate (DCA) in adults with recurrent malignant brain tumors. Invest New Drugs 32(3):452-464.
28. El Gammal AT et al (2010) Chromosome 8p deletions and 8q gains are associated with tumor progression and poor prognosis in prostate cancer. Clin Cancer Res 16(1):56-64.
29. El-Serag HB (2011) Hepatocellular carcinoma. N Engl J Med 365(12):1118-1127.
30. Eroles P et al (2012) Molecular biology in breast cancer: intrinsic subtypes and signaling pathways. Cancer Treat Rev 38(6):698-707.
31. Evans MJ et al (2005) Target discovery in small-molecule cell-based screens by in situ proteome reactivity profiling. Nat Biotechnol 23(10):1303-1307.
32. Falvella FS et al (2002) Stearoyl-CoA desaturase 1 (Scd1) gene overexpression is associated with genetic predisposition to hepatocarcinogenesis in mice and rats. Carcinogenesis 23 (11):1933-1936.
33. Farazi PA, DePinho RA (2006) Hepatocellular carcinoma pathogenesis: from genes to environment. Nat Rev Cancer 6(9):674-687.
34. Feldman BJ, Feldman D (2001) The development of androgen-independent prostate cancer. Nat Rev Cancer 1:34-45.
35. Fendt SM et al (2013a) Reductive glutamine metabolism is a function of the alpha-ketoglutarate to citrate ratio in cells. Nat Commun 4:2236.
36. Fendt S-M et al (2013b) Metformin decreases glucose oxidation and increases the dependency of prostate cancer cells on reductive glutamine metabolism. Cancer Res 73:4429-4438.
37. Fiaschi T et al (2012) Reciprocal metabolic reprogramming through lactate shuttle coordinately influences tumor-stroma interplay. Cancer Res 72:5130-5140.
38. Flavin R et al (2010) Fatty acid synthase as a potential therapeutic target in cancer. Future Oncol 6 (4):551-562.
39. Foulkes WD, Smith IE, Reis-Filho JS (2010) Triple-negative breast cancer. N Engl J Med 363 (20):1938-1948.
40. Franklin RB, Costello LC (2007) Zinc as an anti-tumor agent in prostate cancer and in other cancers. Arch Biochem Biophys 463:211-217.
41. Franz MC et al (2013) Zinc transporters in prostate cancer. Mol Aspects Med 34(2-3):735-741.
42. Friday E et al (2012) Role of glutamate dehydrogenase in cancer growth and homeostasis. In: Dehydrogenases. InTech, Rijeka, Croatia, pp 181-190.
43. Fulda S, Galluzzi L, Kroemer G (2010) Targeting mitochondria for cancer therapy. Nat Rev Drug Discov 9(6):447-464.
44. Fung C, Dale W, Mohile SG (2014) Prostate cancer in the elderly patient. J Clin Oncol 32:2523-2530.
45. Galluzzi L et al (2013) Metabolic targets for cancer therapy. Nat Rev Drug Discov 12(11):829-846.
46. Galmarini CM, Mackey JR, Dumontet C (2002) Nucleoside analogues and nucleobases in cancer treatment. Lancet Oncol 3(7):415-424.
47. Gao SP et al (2007) Mutations in the EGFR kinase domain mediate STAT3 activation via IL-6 production in human lung adenocarcinomas. J Clin Invest 117(12):3846-3856.
48. Gao P et al (2009) c-Myc suppression of miR-23a/b enhances mitochondrial glutaminase expression and glutamine metabolism. Nature 458(7239):762-765.
49. Ghiringhelli F, Apetoh L (2014) Enhancing the anticancer effects of 5-fluorouracil: current challenges and future perspectives. Biomed J.
50. Giatromanolaki A et al (2012) The metabolic interactions between tumor cells and tumorassociated stroma (TAS) in prostatic cancer. Cancer Biol Ther 13:1284-1289.
51. Giatromanolaki A et al (2014) Autophagy proteins in prostate cancer: relation with anaerobic metabolism and Gleason score. Urol Oncol 32:39. e11-8.
52. Giovannucci E et al (2010) Diabetes and cancer: a consensus report. CA Cancer J Clin 60 (4):207-221.
53. Glen A et al (2008) iTRAQ-facilitated proteomic analysis of human prostate cancer cells identifies proteins associated with progression. J Proteome Res 7:897-907.
54. Goidts V et al (2012) RNAi screening in glioma stem-like cells identifies PFKFB4 as a key molecule important for cancer cell survival. Oncogene 31(27):3235-3243.
55. Goldhirsch A et al (2011) Strategies for subtypes-dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011. Ann Oncol 22(8):1736-47.
56. Gong Z et al (2014) Associations of dietary folate, vitamins B6 and B12 and methionine intake with risk of breast cancer among African American and European American women. Int J Cancer 134(6):1422-1435.
57. Goricar K et al (2014) Influence of the folate pathway and transporter polymorphisms on methotrexate treatment outcome in osteosarcoma. Pharmacogenet Genomics 24:514-521.
58. Grasso CS et al (2012) The mutational landscape of lethal castration-resistant prostate cancer. Nature 487(7406):239-243.
59. Groheux D et al (2011) Correlation of high 18F-FDG uptake to clinical, pathological and biological prognostic factors in breast cancer. Eur J Nucl Med Mol Imaging 38(3):426-435.
60. Gross MI et al (2014) Antitumor activity of the glutaminase inhibitor CB-839 in triple-negative breast cancer. Mol Cancer Ther 13(4):890-901.
61. Gurel B et al (2010) NKX3. 1 as a marker of prostatic origin in metastatic tumors. Am J Surg Pathol 34(8):1097-1105.
62. Hamanaka RB, Chandel NS (2012) Targeting glucose metabolism for cancer therapy. J Exp Med 209(2):211-215.
63. Hanahan D, Weinberg RA (2011) Hallmarks of cancer: the next generation. Cell 144(5):646-674.
64. Harris HR, Bergkvist L, Wolk A (2012) Folate intake and breast cancer mortality in a cohort of Swedish women. Breast Cancer Res Treat 132(1):243-250.
65. Hatzivassiliou G et al (2005) ATP citrate lyase inhibition can suppress tumor cell growth. Cancer Cell 8(4):311-321.
66. Heidenreich A et al (2014a) EAU guidelines on prostate cancer. Part 1: screening, diagnosis, and local treatment with curative intent-update 2013. Eur Urol 65(1):124-137.
67. Heidenreich A et al (2014b) EAU guidelines on prostate cancer. Part II: treatment of advanced, relapsing, and castration-resistant prostate cancer. Eur Urol 65(2):467-479.
68. Hensley CT, Wasti AT, DeBerardinis RJ (2013) Glutamine and cancer: cell biology, physiology, and clinical opportunities. J Clin Invest 123(9):3678-3684.
69. Horiuchi D et al (2012) MYC pathway activation in triple-negative breast cancer is synthetic lethal with CDK inhibition. J Exp Med 209(4):679-696.
70. Howlader N et al (2014) US incidence of breast cancer subtypes defined by joint hormone receptor and HER2 status. J Natl Cancer Inst 106(5):1-8.
71. Hu W et al (2010) Glutaminase 2, a novel p53 target gene regulating energy metabolism and antioxidant function. Proc Natl Acad Sci U S A 107(16):7455-7460.
72. Huang Q et al (2014) CD147 promotes reprogramming of glucose metabolism and cell proliferation in HCC cells by inhibiting the p53-dependent signaling pathway. J Hepatol 61(4):859-866.
73. Hunt MC, Tillander V, Alexson SE (2014) Regulation of peroxisomal lipid metabolism: the role of acyl-CoA and coenzyme A metabolizing enzymes. Biochimie 98:45-55.
74. Jadvar H (2011) Prostate cancer: PET with 18F-FDG, 18F-or 11C-acetate, and 18F-or 11C-choline. J Nucl Med 52:81-89.
75. Jadvar H et al (2005) Glucose metabolism of human prostate cancer mouse xenografts. Mol Imaging 4:91-97.
76. Jadvar H et al (2013) Baseline 18F-FDG PET/CT parameters as imaging biomarkers of overall survival in castrate-resistant metastatic prostate cancer. J Nucl Med 54:1195-1201.
77. Jans J et al (2010) Expression and localization of hypoxia proteins in prostate cancer: prognostic implications after radical prostatectomy. Urology 75:786-792.
78. Jemal A et al (2011) Global cancer statistics. CA Cancer J Clin 61(2):69-90.
79. Jeon HM et al (2013) Expression of cell metabolism-related genes in different molecular subtypes of triple-negative breast cancer. Tumori 99(4):555-564.
80. Jin Q et al (2010) Fatty acid synthase phosphorylation: a novel therapeutic target in HER2-overexpressing breast cancer cells. Breast Cancer Res 12(6):R96.
81. Kapanda CN et al (2012) Synthesis and pharmacological evaluation of 2,4-dinitroaryldithiocarbamate derivatives as novel monoacylglycerol lipase inhibitors. J Med Chem 55(12):5774-5783.
82. Karantanos T, Corn PG, Thompson TC (2013) Prostate cancer progression after androgen deprivation therapy: mechanisms of castrate resistance and novel therapeutic approaches. Oncogene 32(49):5501-5511.
83. Keibler MA, Fendt SM, Stephanopoulos G (2012) Expanding the concepts and tools of metabolic engineering to elucidate cancer metabolism. Biotechnol Prog 28(6):1409-1418.
84. Kennecke H et al (2010) Metastatic behavior of breast cancer subtypes. J Clin Oncol 28 (20):3271-3277.
85. Keshari KR et al (2013) Metabolic reprogramming and validation of hyperpolarized 13C lactate as a prostate cancer biomarker using a human prostate tissue slice culture bioreactor. Prostate 73:1171-1181.
86. Khan MA et al (2000) Positron emission tomography scanning in the evaluation of hepatocellular carcinoma. J Hepatol 32(5):792-797.
87. Kim YR et al (2013) HOXB13 downregulates intracellular zinc and increases NF-kappaB signaling to promote prostate cancer metastasis. Oncogene 33:4558-4567.
88. Kitamura K et al (2011) Proliferative activity in hepatocellular carcinoma is closely correlated with glucose metabolism but not angiogenesis. J Hepatol 55(4):846-857.
89. Klarer AC et al (2014) Inhibition of 6-phosphofructo-2-kinase (PFKFB3) induces autophagy as a survival mechanism. Cancer Metab 2(1):2.
90. Koo HR et al (2014) 18F-FDG uptake in breast cancer correlates with immunohistochemically defined subtypes. Eur Radiol 24(3):610-618.
91. Koomoa DL et al (2008) Ornithine decarboxylase inhibition by alpha-difluoromethylornithine activates opposing signaling pathways via phosphorylation of both Akt/protein kinase B and p27Kip1 in neuroblastoma. Cancer Res 68(23):9825-9831.
92. Koukourakis MI et al (2014) Lactate dehydrogenase 5 isoenzyme overexpression defines resistance of prostate cancer to radiotherapy. Br J Cancer 110:2217-2223.
93. Kridel SJ et al (2004) Orlistat is a novel inhibitor of fatty acid synthase with antitumor activity. Cancer Res 64:2070-2075.
94. Kumar S et al (2010) Clinical trials and progress with paclitaxel in ovarian cancer. Int J Womens Health 2:411-427.
95. Kumar-Sinha C et al (2004) Elevated alpha-methylacyl-CoA racemase enzymatic activity in prostate cancer. Am J Pathol 164(3):787-793.
96. Kung HN, Marks JR, Chi JT (2011) Glutamine synthetase is a genetic determinant of cell typespecific glutamine independence in breast epithelia. PLoS Genet 7(8):e1002229.
97. Labuschagne CF et al (2014) Serine, but not glycine, supports one-carbon metabolism and proliferation of cancer cells. Cell Rep 7(4):1248-1258.
98. Larsson SC, Wolk A (2007) Overweight, obesity and risk of liver cancer: a meta-analysis of cohort studies. Br J Cancer 97(7):1005-1008.
99. Lee GY et al (2014a) Comparative oncogenomics identifies PSMB4 and SHMT2 as potential cancer driver genes. Cancer Res 74(11):3114-3126.
100. Lee JM et al (2014b) beta-Catenin signaling in hepatocellular cancer: implications in inflammation, fibrosis, and proliferation. Cancer Lett 343(1):90-97.
101. Lee YH et al (2014c) Antitumor effects in hepatocarcinoma of isoform-selective inhibition of HDAC2. Cancer Res 74(17):4752-4761.
102. Leiblich A et al (2006) Lactate dehydrogenase-B is silenced by promoter hypermethylation in human prostate cancer. Oncogene 25:2953-2960.
103. Levitsky LL et al (1994) GLUT-1 and GLUT-2 mRNA, protein, and glucose transporter activity in cultured fetal and adult hepatocytes. Am J Physiol 267(1 Pt 1):E88-E94.
104. Li C et al (2011) Green tea polyphenols control dysregulated glutamate dehydrogenase in transgenic mice by hijacking the ADP activation site. J Biol Chem 286(39):34164-34174.
105. Lim KS et al (2014) Inhibition of monocarboxylate transporter-4 depletes stem-like glioblastoma cells and inhibits HIF transcriptional response in a lactate-independent manner. Oncogene 33 (35):4433-4441.
106. Liu Y (2006) Fatty acid oxidation is a dominant bioenergetic pathway in prostate cancer. Prostate Cancer Prostatic Dis 9:230-234.
107. Liu Y, Zuckier LS, Ghesani NV (2010) Dominant uptake of fatty acid over glucose by prostate cells: a potential new diagnostic and therapeutic approach. Anticancer Res 30:369-374.
108. Liu X, Fu YM, Meadows GG (2011) Differential effects of specific amino acid restriction on glucose metabolism, reduction/oxidation status and mitochondrial damage in DU145 and PC3 prostate cancer cells. Oncol Lett 2(2):349-355.
109. Liu W et al (2012a) Reprogramming of proline and glutamine metabolism contributes to the proliferative and metabolic responses regulated by oncogenic transcription factor c-MYC. Proc Natl Acad Sci U S A 109(23):8983-8988.
110. Liu Y et al (2012b) A small-molecule inhibitor of glucose transporter 1 downregulates glycolysis, induces cell-cycle arrest, and inhibits cancer cell growth in vitro and in vivo. Mol Cancer Ther 11(8):1672-1682.
111. Locasale JW (2013) Serine, glycine and one-carbon units: cancer metabolism in full circle. Nat Rev Cancer 13(8):572-583.
112. Locasale JW et al (2011) Phosphoglycerate dehydrogenase diverts glycolytic flux and contributes to oncogenesis. Nat Genet 43(9):869-874.
113. Long J et al (2011) Expression level of glutamine synthetase is increased in hepatocellular carcinoma and liver tissue with cirrhosis and chronic hepatitis B. Hepatol Int 5(2):698-706.
114. Lu C et al (2012) IDH mutation impairs histone demethylation and results in a block to cell differentiation. Nature 483(7390):474-478.
115. Lund K, Merrill DK, Guynn RW (1985) The reactions of the phosphorylated pathway of L-serine biosynthesis: thermodynamic relationships in rabbit liver in vivo. Arch Biochem Biophys 237 (1):186-196.
116. Lu-Yao GL et al (2009) Outcomes of localized prostate cancer following conservative management. JAMA 302:1202-1209.
117. Ma R et al (2013) Switch of glycolysis to gluconeogenesis by dexamethasone for treatment of hepatocarcinoma. Nat Commun 4:2508.
118. Mano Y et al (2014) Correlation between biological marker expression and fluorine-18 fluorodeoxyglucose uptake in hepatocellular carcinoma. Am J Clin Pathol 142(3):391-397.
119. Martinez-Outschoorn UE et al (2010a) Tumor cells induce the cancer associated fibroblast phenotype via caveolin-1 degradation: implications for breast cancer and DCIS therapy with autophagy inhibitors. Cell Cycle 9(12):2423-2433.
120. Martinez-Outschoorn UE et al (2010b) Autophagy in cancer associated fibroblasts promotes tumor cell survival: role of hypoxia, HIF1 induction and NFkappaB activation in the tumor stromal microenvironment. Cell Cycle 9(17):3515-3533.
121. Massie CE et al (2011) The androgen receptor fuels prostate cancer by regulating central metabolism and biosynthesis. EMBO J 30:2719-2733.
122. McBrayer SK et al (2012) Multiple myeloma exhibits novel dependence on GLUT4, GLUT8, and GLUT11: implications for glucose transporter-directed therapy. Blood 119(20):4686-4697.
123. McCleland ML et al (2012) An integrated genomic screen identifies LDHB as an essential gene for triple-negative breast cancer. Cancer Res 72(22):5812-5823.
124. Mena E et al (2012) 11C-Acetate PET/CT in localized prostate cancer: a study with MRI and histopathologic correlation. J Nucl Med 53:538-545.
125. Metallo CM, Vander Heiden MG (2013) Understanding metabolic regulation and its influence on cell physiology. Mol Cell 49(3):388-398.
126. Migita T et al (2014) Inhibition of ATP citrate lyase induces triglyceride accumulation with altered fatty acid composition in cancer cells. Int J Cancer 135(1):37-47.
127. Mihelich BL et al (2011) miR-183-96-182 cluster is overexpressed in prostate tissue and regulates zinc homeostasis in prostate cells. J Biol Chem 286(52):44503-44511.
128. Minamimoto R et al (2011) The potential of FDG-PET/CT for detecting prostate cancer in patients with an elevated serum PSA level. Ann Nucl Med 25:21-27.
129. Moeini A, Cornella H, Villanueva A (2012) Emerging signaling pathways in hepatocellular carcinoma. Liver Cancer 1(2):83-93.
130. Moon J-S et al (2011) Androgen stimulates glycolysis for de novo lipid synthesis by increasing the activities of hexokinase 2 and 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase 2 in prostate cancer cells. Biochem J 433:225-233.
131. Muller HJ, Boos J (1998) Use of L-asparaginase in childhood ALL. Crit Rev Oncol Hematol 28 (2):97-113.
132. Neradil J, Pavlasova G, Veselska R (2012) New mechanisms for an old drug; DHFR-and non-DHFR-mediated effects of methotrexate in cancer cells. Klin Onkol 25(Suppl 2):2s87-2s92.
133. Ni Y, Schwaneberg U, Sun ZH (2008) Arginine deiminase, a potential anti-tumor drug. Cancer Lett 261(1):1-11.
134. Nielsen SF, Nordestgaard BG, Bojesen SE (2012) Statin use and reduced cancer-related mortality. N Engl J Med 367(19):1792-1802.
135. Niva CC, Lee JM, Myohara M (2008) Glutamine synthetase gene expression during the regeneration of the annelid Enchytraeus japonensis. Dev Genes Evol 218(1):39-46.
136. Nomura DK et al (2010) Monoacylglycerol lipase regulates a fatty acid network that promotes cancer pathogenesis. Cell 140(1):49-61.
137. Oppong BA et al (2014) The effect of metformin on breast cancer outcomes in patients with type 2 diabetes. Cancer Med 3(4):1025-1034.
138. Oyama N et al (1999) The increased accumulation of [18F]fluorodeoxyglucose in untreated prostate cancer. Jpn J Clin Oncol 29:623-629.
139. Pértega-Gomes N et al (2014) A lactate shuttle system between tumour and stromal cells is associated with poor prognosis in prostate cancer. BMC Cancer 14:352.
140. Pierobon M, Frankenfeld CL (2013) Obesity as a risk factor for triple-negative breast cancers: a systematic review and meta-analysis. Breast Cancer Res Treat 137(1):307-314.
141. Petrut B, Trinkaus M, Simmons C, Clemons M (2008) A primer of bone metastases management in breast cancer patients. Curr Oncol 15(Suppl 1):S50-S57.
142. Polanski R et al (2014) Activity of the monocarboxylate transporter 1 inhibitor AZD3965 in small cell lung cancer. Clin Cancer Res 20(4):926-937.
143. Pollari S et al (2011) Enhanced serine production by bone metastatic breast cancer cells stimulates osteoclastogenesis. Breast Cancer Res Treat 125(2):421-430.
144. Popovici-Muller J et al (2012) Discovery of the first potent inhibitors of mutant IDH1 that lower tumor 2-HG in vivo. ACS Med Chem Lett 3(10):850-855.
145. Porporato PE et al (2011) Anticancer targets in the glycolytic metabolism of tumors: a comprehensive review. Front Pharmacol 2:49.
146. Possemato R et al (2011) Functional genomics reveal that the serine synthesis pathway is essential in breast cancer. Nature 476(7360):346-350.
147. Puszyk WM et al (2013) Linking metabolism and epigenetic regulation in development of hepatocellular carcinoma. Lab Invest 93(9):983-990.
148. Reinicke K et al (2012) Cellular distribution of glut-1 and glut-5 in benign and malignant human prostate tissue. J Cell Biochem 113:553-562.
149. Ren JG et al (2010) Induction of erythroid differentiation in human erythroleukemia cells by depletion of malic enzyme 2. PLoS One 5(9):1-12.
150. Ren JG et al (2014) Knockdown of malic enzyme 2 suppresses lung tumor growth, induces differentiation and impacts PI3K/AKT signaling. Sci Rep 4:5414.
151. Rizos CV, Elisaf MS (2013) Metformin and cancer. Eur J Pharmacol 705(1-3):96-108.
152. Rohle D et al (2013) An inhibitor of mutant IDH1 delays growth and promotes differentiation of glioma cells. Science 340(6132):626-630.
153. Ros S, Schulze A (2013) Balancing glycolytic flux: the role of 6-phosphofructo-2-kinase/fructose 2,6-bisphosphatases in cancer metabolism. Cancer Metab 1:8.
154. Ros S et al (2012) Functional metabolic screen identifies 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 4 as an important regulator of prostate cancer cell survival. Cancer Discov 2:328-343.
155. Ross J et al (2008) Fatty acid synthase inhibition results in a magnetic resonance-detectable drop in phosphocholine. Mol Cancer Ther 7(8):2556-2565.
156. Rossi S et al (2003) Fatty acid synthase expression defines distinct molecular signatures in prostate cancer. Mol Cancer Res 1:707-715.
157. Roychowdhury S, Chinnaiyan AM (2013) Advancing precision medicine for prostate cancer through genomics. J Clin Oncol Off J Am Soc Clin Oncol 31:1866-1873.
158. Rubin MA et al (2002) alpha-Methylacyl coenzyme A racemase as a tissue biomarker for prostate cancer. JAMA 287(13):1662-1670.
159. Rubin MA, Maher CA, Chinnaiyan AM (2011) Common gene rearrangements in prostate cancer. J Clin Oncol 29(27):3659-3668.
160. Sanità P et al (2014) Tumor-stroma metabolic relationship based on lactate shuttle can sustain prostate cancer progression. BMC Cancer 14:154.
161. Santidrian AF et al (2013) Mitochondrial complex I activity and NAD+/NADH balance regulate breast cancer progression. J Clin Invest 123(3):1068-1081.
162. Schlaepfer IR et al (2014) Lipid catabolism via CPT1 as a therapeutic target for prostate cancer. Mol Cancer Ther 13:2361-2371, p. molcanther. 0183. 2014.
163. Schoors S et al (2014) Partial and transient reduction of glycolysis by PFKFB3 blockade reduces pathological angiogenesis. Cell Metab 19(1):37-48.
164. Shen MM, Abate-Shen C (2010) Molecular genetics of prostate cancer: new prospects for old challenges. Genes Dev 24:1967-2000.
165. Shonk CE, Morris HP, Boxer GE (1965) Patterns of glycolytic enzymes in rat liver and hepatoma. Cancer Res 25:671-676.
166. Shrubsole MJ et al (2011) Dietary B vitamin and methionine intakes and breast cancer risk among Chinese women. Am J Epidemiol 173(10):1171-1182.
167. Sonveaux P et al (2008) Targeting lactate-fueled respiration selectively kills hypoxic tumor cells in mice. J Clin Invest 118(12):3930-3942.
168. Sotgia F et al (2011) Understanding the Warburg effect and the prognostic value of stromal caveolin-1 as a marker of a lethal tumor microenvironment. Breast Cancer Res 13(4):213.
169. Stein M et al (2010) Targeting tumor metabolism with 2-deoxyglucose in patients with castrateresistant prostate cancer and advanced malignancies. Prostate 70:1388-1394.
170. Stein E et al (2014) Clinical safety and activity in a phase I trial of AG-221, a first in class, potent inhibitor of the IDH2-mutant protein, in patients with IDH2 mutant positive advanced hematologic malignancies. In: Proceedings of the 105th annual meeting of the American Association for Cancer Research.
171. Sung J et al (2003) Fluorodeoxyglucose positron emission tomography studies in the diagnosis and staging of clinically advanced prostate cancer. BJU Int 92:24-27.
172. Sweeney MJ et al (1963) Comparative biochemistry hepatomas. IV. Isotope studies of glucose and fructose metabolism in liver tumors of different growth rates. Cancer Res 23:995-1002.
173. Swinnen JV et al (2002) Overexpression of fatty acid synthase is an early and common event in the development of prostate cancer. Int J Cancer 98:19-22.
174. Taketa K et al (1988) Profiles of carbohydrate-metabolizing enzymes in human hepatocellular carcinomas and preneoplastic livers. Cancer Res 48(2):467-474.
175. Taylor BS et al (2010) Integrative genomic profiling of human prostate cancer. Cancer Cell 18 (1):11-22.
176. Tchou J et al (2010) Degree of tumor FDG uptake correlates with proliferation index in triple negative breast cancer. Mol Imaging Biol 12(6):657-662.
177. Telang S et al (2014) Discovery of a PFKFB3 inhibitor for phase I trial testing that synergizes with the B-Raf inhibitor vemurafenib. Cancer Metab 2(Suppl 1):P14.
178. Tennakoon JB et al (2013) Androgens regulate prostate cancer cell growth via an AMPK-PGC-1α-mediated metabolic switch. Oncogene 33:5251-5261.
179. Tennant DA, Duran RV, Gottlieb E (2010) Targeting metabolic transformation for cancer therapy. Nat Rev Cancer 10(4):267-277.
180. Tessem M-B et al (2008) Evaluation of lactate and alanine as metabolic biomarkers of prostate cancer using 1H HR-MAS spectroscopy of biopsy tissues. Magn Reson Med 60:510-516.
181. Thorgeirsson SS, Grisham JW (2002) Molecular pathogenesis of human hepatocellular carcinoma. Nat Genet 31(4):339-346.
182. Timmerman LA et al (2013) Glutamine sensitivity analysis identifies the xCT antiporter as a common triple-negative breast tumor therapeutic target. Cancer Cell 24(4):450-465.
183. Tomlinson IP et al (2002) Germline mutations in FH predispose to dominantly inherited uterine fibroids, skin leiomyomata and papillary renal cell cancer. Nat Genet 30(4):406-410.
184. Torizuka T et al (1995) In vivo assessment of glucose metabolism in hepatocellular carcinoma with FDG-PET. J Nucl Med 36(10):1811-1817.
185. Tsouko E et al (2014) Regulation of the pentose phosphate pathway by an androgen receptormTOR-mediated mechanism and its role in prostate cancer cell growth. Oncogenesis 3:e103.
186. Tsuchiyama K et al (2013) Expression of microRNAs associated with Gleason grading system in prostate cancer: miR-182-5p is a useful marker for high grade prostate cancer. Prostate 73 (8):827-834.
187. Tsui KH et al (2011) p53 downregulates the gene expression of mitochondrial aconitase in human prostate carcinoma cells. Prostate 71(1):62-70.
188. Tsui KH et al (2013) Hypoxia upregulates the gene expression of mitochondrial aconitase in prostate carcinoma cells. J Mol Endocrinol 51(1):131-141.
189. Turcan S et al (2012) IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype. Nature 483(7390):479-483.
190. Van de Sande T et al (2002) Role of the phosphatidylinositol 30-kinase/PTEN/Akt kinase pathway in the overexpression of fatty acid synthase in LNCaP prostate cancer cells. Cancer Res 62 (3):642-646.
191. Van de Sande T et al (2005) High-level expression of fatty acid synthase in human prostate cancer tissues is linked to activation and nuclear localization of Akt/PKB. J Pathol 206(2):214-219.
192. Vander Heiden MG (2011) Targeting cancer metabolism: a therapeutic window opens. Nat Rev Drug Discov 10(9):671-684.
193. Vander Heiden MG et al (2010) Identification of small molecule inhibitors of pyruvate kinase M2. Biochem Pharmacol 79(8):1118-1124.
194. Vaz CV et al (2012) Androgen-responsive and nonresponsive prostate cancer cells present a distinct glycolytic metabolism profile. Int J Biochem Cell Biol 44:2077-2084.
195. Visser WF et al (2007) Metabolite transport across the peroxisomal membrane. Biochem J 401 (2):365-375.
196. Voduc KD et al (2010) Breast cancer subtypes and the risk of local and regional relapse. J Clin Oncol 28(10):1684-1691.
197. Walling J (2006) From methotrexate to pemetrexed and beyond. A review of the pharmacodynamic and clinical properties of antifolates. Invest New Drugs 24(1):37-77.
198. Walsh MJ et al (2010) ML265: a potent PKM2 activator induces tetramerization and reduces tumor formation and size in a mouse xenograft model. In: Probe reports from the NIH Molecular Libraries Program, Bethesda, MD.
199. Walsh AL et al (2014) Long noncoding RNAs and prostate carcinogenesis: the missing 'linc'? Trends Mol Med 20(8):428-436.
200. Wang JB et al (2010) Targeting mitochondrial glutaminase activity inhibits oncogenic transformation. Cancer Cell 18(3):207-219.
201. Wang B et al (2012) Stat3-mediated activation of microRNA-23a suppresses gluconeogenesis in hepatocellular carcinoma by down-regulating glucose-6-phosphatase and peroxisome proliferator-activated receptor gamma, coactivator 1 alpha. Hepatology 56(1):186-197.
202. Wang F et al (2013) Targeted inhibition of mutant IDH2 in leukemia cells induces cellular differentiation. Science 340(6132):622-626.
203. Weber G, Ashmore J (1958) Absent fructose-1,6-diphosphatase activity in hepatoma. Exp Cell Res 14(1):226-228.
204. Weber G, Cantero A (1955) Glucose-6-phosphatase activity in normal, pre-cancerous, and neoplastic tissues. Cancer Res 15(2):105-108.
205. Weber G, Morris HP (1963) Comparative biochemistry of hepatomas. III. Carbohydrate enzymes in liver tumors of different growth rates. Cancer Res 23:987-994.
206. Weischenfeldt J et al (2013) Integrative genomic analyses reveal an androgen-driven somatic alteration landscape in early-onset prostate cancer. Cancer Cell 23(2):159-170.
207. Wu JM, Skill NJ, Maluccio MA (2010) Evidence of aberrant lipid metabolism in hepatitis C and hepatocellular carcinoma. HPB (Oxford) 12(9):625-636.
208. Xu X, Chen J (2009) One-carbon metabolism and breast cancer: an epidemiological perspective. J Genet Genomics 36(4):203-214.
209. Yalcin A et al (2010) Selective inhibition of choline kinase simultaneously attenuates MAPK and PI3K/AKT signaling. Oncogene 29(1):139-149.
210. Yan H et al (2009) IDH1 and IDH2 mutations in gliomas. N Engl J Med 360(8):765-773.
211. Yang B et al (2003) Aberrant promoter methylation profiles of tumor suppressor genes in hepatocellular carcinoma. Am J Pathol 163(3):1101-1107.
212. Yang Y et al (2007) Metabonomic studies of human hepatocellular carcinoma using highresolution magic-angle spinning 1H NMR spectroscopy in conjunction with multivariate data analysis. J Proteome Res 6(7):2605-2614.
213. Yang C et al (2009) Glioblastoma cells require glutamate dehydrogenase to survive impairments of glucose metabolism or Akt signaling. Cancer Res 69(20):7986-7993.
214. Yeh SDJ et al (1996) Detection of bony metastases of androgen-independent prostate cancer by PET-FDG. Nucl Med Biol 23:693-697.
215. Yeruva L et al (2010) Perillyl alcohol and methyl jasmonate sensitize cancer cells to cisplatin. Anticancer Drugs 21(1):1-9.
216. Yoshimoto S et al (2013) Obesity-induced gut microbial metabolite promotes liver cancer through senescence secretome. Nature 499(7456):97-101.
217. Yue S et al (2014) Cholesteryl ester accumulation induced by PTEN loss and PI3K/AKT activation underlies human prostate cancer aggressiveness. Cell Metab 19(3):393-406.
218. Zadra G, Photopoulos C, Loda M (2013) The fat side of prostate cancer. Biochim Biophys Acta Mol Cell Biol Lipids 1831:1518-1532.
219. Zaugg K et al (2011) Carnitine palmitoyltransferase 1C promotes cell survival and tumor growth under conditions of metabolic stress. Genes Dev 25(10):1041-1051.
220. Zecchini V et al (2014) Nuclear ARRB1 induces pseudohypoxia and cellular metabolism reprogramming in prostate cancer. EMBO J 33:1365-1382.
221. Zha S et al (2005) Peroxisomal branched chain fatty acid beta-oxidation pathway is upregulated in prostate cancer. Prostate 63:316-323.
222. Zhang SM et al (2003) Plasma folate, vitamin B6, vitamin B12, homocysteine, and risk of breast cancer. J Natl Cancer Inst 95(5):373-380.
223. Zhang CX et al (2011) Dietary folate, vitamin B6, vitamin B12 and methionine intake and the risk of breast cancer by oestrogen and progesterone receptor status. Br J Nutr 106(6):936-943.
224. Zhang WC et al (2012) Glycine decarboxylase activity drives non-small cell lung cancer tumorinitiating cells and tumorigenesis. Cell 148(1-2):259-272.
225. Zhang C et al (2013) IDH1/2 mutations target a key hallmark of cancer by deregulating cellular metabolism in glioma. Neuro Oncol 15(9):1114-1126.
226. Zheng Q et al (1995) Glucose regulation of glucose transporters in cultured adult and fetal hepatocytes. Metabolism 44(12):1553-1558.
227. Zheng MF, Shen SY, Huang WD (2013) DCA increases the antitumor effects of capecitabine in a mouse B16 melanoma allograft and a human non-small cell lung cancer A549 xenograft. Cancer Chemother Pharmacol 72(5):1031-1041.
228. Zou J et al (2011) hZIP1 zinc transporter down-regulation in prostate cancer involves the overexpression of ras responsive element binding protein-1 (RREB-1). Prostate 71:1518-1524.